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*Pseudomonas* sp. is ubiquitously present worldwide of which *Pseudomonas aeruginosa* is a major nosocomial pathogen, which survives in moist environments and colonizes the respiratory tract of mechanically ventilated patients.\[[@ref1]\] It causes severe infections such as pneumonia in critically ill and immunocompromised patients. Multidrug-resistant (MDR) *P. aeruginosa* is especially associated with increased mortality because no adequate therapeutic option exists.\[[@ref2]\] MDR strains of *P. aeruginosa* were initially reported in patients with cystic fibrosis.\[[@ref3][@ref4]\] MDR in *P. aeruginosa* or *Acinetobacter* spp. has been variously defined.\[[@ref4][@ref5]\] Recently, it has been proposed that the term "extensive drug resistance" should be used to indicate resistance to all, but one or two classes of antimicrobial agents.\[[@ref6]\]

Though many studies have been done on infections caused by *Pseudomonas* sp. and its drug resistance in different patients more so in patients with cystic fibrosis, but it is scarce among trauma patients. Hence, we have tried to study the distribution of different *Pseudomonas* spp., its antimicrobial resistance against commonly used antibiotics and the outcomes of such infections. Furthermore, we have tried to analyze, which type of trauma patients were mainly infected with multi drug resistant *Pseudomonas*.

This was a retrospective cross-sectional analysis of all the *Pseudomonas* isolates obtained from different samples of patients admitted in different wards of Jai Prakash Narayan Apex Trauma Center, New Delhi, India from January 2007 to December 2012. All the results were noted from the microbiology database and the resistance pattern observed and analyzed.

All the microbiology samples were scanned and the samples isolating *Pseudomonas* sp. were taken into consideration irrespective of their preoperative nor postoperative collection. All these samples were processed as per standard microbiological methods.\[[@ref7]\] The bacterial isolates were identified to the species level by the VITEK 2^®^ compact system (BioMérieux, Lyon, France). The antimicrobial susceptibility testing were done by the disc diffusion method, according to the Clinical and Laboratory Standard Institute (CLSI) guidelines\[[@ref8][@ref9]\] and the VITEK 2 system. Mueller --- Hinton agar (HiMedia, Mumbai, India) was used uniformly for all the sensitivity testing and incubated aerobically at 37°C. ATCC control strains of *P. aeruginosa* (ATCC 27853) and *Escherichia coli* (ATCC 25922) were used as quality control. All isolates in this were nonduplicate.

The standardized custom sensitivity panel used in the VITEK 2 included 25 different antimicrobials for susceptibility testing of all Gram-negative isolates, but for this study only the susceptibilities of *Pseudomonas* spp. to common antipseudomonal agents were analyzed.

For this study, multi-drug resistance was defined as resistance of a *Pseudomonas* isolate to at least three of the following four drugs: Amikacin, imipenem, ceftazidime, ciprofloxacin and tobramycin. These antibiotics were chosen because they are representative of their antibiotic classes and their minimum inhibitory concentrations (MICs) were tested throughout the study period (2007 -2012). Antibiotics with intermediate susceptibility CLSI were considered resistant in the study analysis. Cross-resistance to formulary antibiotics were also evaluated for its efficacy in its empiric therapy. MDR *P. aeruginosa* was defined as *P. aeruginosa* resistant or intermediate to imipenem (MIC \>8 mg/L), levofloxacin (MIC \>8 mg/L) and amikacin (MIC \>64 mg/L) according to CLSI criteria.\[[@ref9]\] Furthermore, definitions of MDR *Pseudomonas* in other studies were noted too.\[[@ref10]\]

Statistical analyses were performed using the SPSS software for Windows (SPSS Inc., Chicago, IL, USA, version 15.0).

A total of 2,269 nonduplicate *Pseudomonas* sp. were isolated. The mean age of the patients from whom they were isolated was 32 years (\[1 -87 years\], standard deviation of 15.1). Male patients (1,875, 82.6%) outnumbers female patients (394, 17.4%) from whom *Pseudomonas* spp. were isolated. In male patients, the mean age was 33 years with a range of 1 -87 years (± 14.22), whereas in female patients, the mean age was found to be 30 years with a range of 2 -83 years (± 18.38). Hence, the *P* value of the means of the age in male and female patients was 0.002 (95% confidence interval = 0.9481 -4.2187).

Of the total 2,269 isolates, the species which was maximally isolated was *P. aeruginosa* (2,224, 98%) followed by *Pseudomonas putida* (25, 1.1%), *Pseudomonas stutzeri* (8, 0.4%), *Pseudomonas luteola* (5, 0.2%), *Pseudomonas flavescens* (5, 0.2%), *Pseudomonas alcaligenes* (1) and *Pseudomonas mendocena* (1) in decreasing order of frequency. The most common sample from which *P. aeruginosa* was recovered was from urine samples (636, 29%), followed by tracheal aspirates (543, 24.4%), pus/wound swabs (442, 20%), blood (172, 8%), bronchalveolar lavage (171, 8%), cerebrospinal fluid (141), central vascular tips (43, 2%), drain fluids (27, 1.2%), tissues (12, 1%), pleural fluid (9, 0.4%), sputum (3,0.1%), bone (2, 0.1%) and others (11,1%). Among *P. putida*, maximum isolation was seen in pus samples (11, 44%), and followed by urine (5, 20%), tracheal aspirates (5, 20%) and equally by blood (2, 8%) and tissue (2, 8%). However, the highest rate of isolation was from blood samples (4, 50%) in *P. stutzeri* followed by equal isolation from urine (2, 25%) and pus/wound samples (2, 25%) each. Only a single isolate each of *P. alcaligenes* was obtained from urine sample and also *P. mendocina* from tissue. In *P. luteola*, maximum isolation was from urine (3, 60%) and equally from tracheal aspirate (1, 20%) and wound swab (1, 20%). Maximum isolation of *P. flavescens* was from blood (3, 60%) followed by bronchoalveolar lavage sample (2, 40%).

The sensitivity pattern of the different species of *Pseudomonas* isolated during this study period is given in [Table 1](#T1){ref-type="table"}. The highest level of resistance was seen in tetracycline (2,166, 95.5%, *P* \< 0.001) and chloramphenicol (2,160, 95.2%, *P* \< 0.001) and least in meropenem (1739, 76.7%, *P* \< 0.003). *P* value of either \<0.001 or \<0.003 shows that the drug resistance is indeed significant and hence treatment with such antibiotics will not show much response.
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Antimicrobial resistance pattern among the different *Pseudomonas* spp. to the various antibiotics used for its treatment
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It was found that a total of 1,692 (74.6%) isolates were MDR. Also, a higher isolation rate of MDR was seen among the male patients (1,406, 75.0%) compared with the female patients (286, 72.6%) admitted for trauma care (χ^2^ = 0.987 and difference of freedom = 1).

*Pseudomonas* sp. was maximally isolated from the samples of patients admitted to the neurosurgery ward (781) followed by neurosurgery Intensive Care Unit (ICU) (568), surgery ICU (436), surgery ward (233), orthopedic ward (160), follow-up patients (70) and emergency department (16). Of the total isolates from different wards, maximum MDR *Pseudomonas* sp. were obtained from neurosurgery ward 605 (77.5%), followed by 453 (79.8%) MDR isolates from the neurosurgery ICU, 335(77.2%) from surgery ward, 91 (56.9%) from orthopedic ward, 40 (75.5%) from follow-up outpatient department and 6 (54.5%) from emergency. Its *P* \< 0.001 which is highly significant (χ^2^ = 79.98, degree of freedom = 14).

When we analyzed the distribution of MDR *Pseudomonas* \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\] among the different species obtained during the study period, *P. aeruginosa* accounted for the maximum MDR isolates with a total number of 1,667 (75%), followed in decreasing frequency by *P. putida* (14, 56%), *P. luteola* (4,80%), *P. flavescens* (4, 80%), *P. stutzeri* (2, 25%) and *P. alcaligenes* (1). However, no MDR was isolated among the *P. mandocina*. A *P* = 0.005 was seen (χ^2^ = 18.51, degree of freedom = 6) and hence not significant.
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Of the total 2,269 nonduplicate *Pseudomonas* spp., the pathogen was responsible for infections in 68% of the patients for whom their treatment had to be revised but later discharged healthy, 12% resulted in death and remaining 20% required no extra interventions in treatment protocol and the patients improved after removing the offending implant/devices or after minor debridement. Here, it was seen that more than 90% among the 20% *Pseudomonas* spp. were mostly colonizers as testing of their surrounding areas or instruments showed the same. So a simple cleaning was able to remove them.

Furthermore, it was observed that infections due to *Pseudomonas* spp. was more in the postoperative patients (1927, 84.9%) and those who are in the hospital for a long time hinting at the hospital acquired infections compared to that of the preoperative patients (342, 15%).

In this study, VITEK and CLSI antibiograms of 2,269 *Pseudomonas* spp. isolates from inpatients, outpatients of our trauma care facility, *P. aeruginosa* was categorized as the most important nosocomial pathogens among the MDR Gram-negative bacilli similar to a report from the Infectious Diseases Society of America.\[[@ref11]\] In our study, even though the rate of isolation of *P. aeruginosa* was 98%, more than 68% of the patients improved after change of therapy and 12% of them had a fatal outcome.

In another retrospective case-control study in Turkey, it was found that the major risk factors for infection or colonization with multi-resistant *P. aeruginosa* were prolonged stay in the ICU, previous and lengthy imipenem usage, and mechanical ventilation.\[[@ref12]\] Also, in our study, maximum isolates of *Pseudomonas* spp. were from the ICUs irrespective of the type of ICU. Our study observed an increase from 11.3% at the start of the study to 58% during the end of the study.

Prior fluoroquinolone use has been identified as a risk factor for the emergence of imipenem-resistant *P. aeruginosa*.\[[@ref13][@ref14]\] Out of 1,797 imipenem-resistant *P. aeruginosa* isolated during the study period, 1,763(98%) showed resistance to ciprofloxacin or levofloxacin, suggesting that cross-resistance may have developed for imipenem due to prior use of fluoroquinolones.

Pan-drug resistance from the MDR *Pseudomonas* isolated were those isolates resistant to all the antibiotics except colistin.\[[@ref10]\] A total of 847 pan-drug resistant *Pseudomonas* were isolated and like the MDR isolates, a steady increase in pan-drug resistant *Pseudomonas* was seen over the study period in our set-up. We have also seen a high rate of isolation during the winter months compared with the summer months which may be influenced by the rate of patient admission pattern.

Though *P. aeruginosa* remained the predominant pathogen, other non-*P. aeruginosa* pathogens are also increasing as causative agents of nosocomial infections in trauma patients. However, our study found no mortality associated with the non-*P. aeruginosa* pathogens.

CONCLUSION {#sec1-2}
==========

*Pseudomonas aeruginosa* is one of the most common causes of nosocomial infection in trauma patients, which is becoming highly drug resistant. Proper and timely use of antimicrobials is the need of the hour.
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